Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 2/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420836 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL25503292 | 0.84 | KDM4E (0.41) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL11086636 | 0.84 | ALDH1A1 (0.44) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL29380304 | 0.82 | ALDH1A1 (0.38) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL1338461 | 0.82 | ALDH1A1 (0.38) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL620246 | 0.78 | CSNK1A1 (0.41) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL31511514 | 0.78 | CSNK1A1 (0.41) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL8139272 | 0.78 | KDM4E (0.40) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL4424103 | 0.78 | CSNK1A1 (0.46) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 | |
| SCHEMBL30826009 | 0.78 | ALDH1A1 (0.40) | ALDH1A1KDM4EPOLBCSNK1A1CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 374 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117208902-A | Preparation method and application of triazine-pyrazinyl nitrogen-rich nitrogen-doped porous carbon material | 常州大学 | 2023-12-12 | — | — | CN | claimed |
| CN-113252800-A | HPLC (high performance liquid chromatography) detection method for Pilarvir and related substances thereof and application of method | 北京四环制药有限公司 | 2021-08-13 | — | — | CN | claimed |
| CN-112062728-A | Synthetic method of 3, 5-dichloro-6-ethylpyrazine formamide | 上海鑫凯化学科技有限公司 | 2020-12-11 | — | — | CN | claimed |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4234030-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12583852-B2 | Heterocycle derivative | JW PHARMACEUTICAL CORPORATION (KR) | 2026-03-24 | — | — | US | disclosed |
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260001892-A1 | COMPOUND FOR REGULATING AND CONTROLLING ACTIVITY OF 15-PGDH AND PREPARATION METHOD THEREFOR | SCINNOHUB PHARMACEUTICAL CO LTD (CN) | 2026-01-01 | — | — | US | disclosed |
| EP-2570415-A1 | N-[4-(1h-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2013-03-20 | — | — | EP | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | PSMB2, PSME3, PSMB3 | ALDH1A1 4614/4885KDM4E 1543/4885POLB 1902/4885 |
| US-20260001892-A1 | COMPOUND FOR REGULATING AND CONTROLLING ACTIVITY OF 15-PGDH AND PREPARATION METHOD THEREFOR | CYP11B1, HSD11B1, CYP11B2 | ALDH1A1 114/4885KDM4E 3341/4885POLB 1275/4885 |
| US-12583852-B2 | Heterocycle derivative | AR, SRD5A1, NR5A1 | ALDH1A1 1733/4885KDM4E 413/4885POLB 4201/4885 |
| US-20260035378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, PSMB2, PSMB1 | ALDH1A1 4621/4885KDM4E 999/4885POLB 2338/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | ALDH1A1 4714/4885KDM4E 810/4885POLB 2490/4885 |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, BCL9, BCL9L | ALDH1A1 4642/4885KDM4E 530/4885POLB 3718/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | ALDH1A1 2651/4885KDM4E 1159/4885POLB 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.